Navigation Links
Dependence in Biological Technology

Human Genome Sciences Announces Closing of Public Offering

... Genome Sciences' unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... property protection, Human Genome Sciences' dependence on key management and key suppliers, the ...

Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results

... regulation of the pharmaceutical industry; our dependence on a small number of products and on outside manufacturers for the manufacture of our products; our dependence on third parties to supply raw materials and to ... litigation or claims by the government; our dependence on sales to a limited number of large pharmacy ...

Neurocrine Biosciences Reports Second Quarter 2009 Results

... trials; and risks associated with the Company's dependence on corporate collaborators for development, ... candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial ...

Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis

... trials; risk associated with the Company's dependence on corporate collaborators for development, ... candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial ...

Human Genome Sciences Announces Pricing of Public Offering of Common Stock

... Genome Sciences' unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... property protection, Human Genome Sciences' dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Proposed Public Offering of Common Stock

... Genome Sciences' unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... property protection, Human Genome Sciences' dependence on key management and key suppliers, the ...

Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease

... #P3-221: Predicting Costs of Care for Unique dependence Levels in Patients with AD (Murman DL, et al.) ... relationship between total costs and AD dependence levels, with costs increasing significantly with increasing dependence. In this study, dependence level provided a useful method to estimate unique ...

Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update

... market opportunity for Helix's products; Helix's dependence on its contractors, consultants, advisors and ... the drug candidate and on the Company; Helix's dependence on its licensor of the L-DOS47 antibody; the need ... which may arise out of DOS47; the Company's dependence on a few customers and a few suppliers, the loss ...

Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

DuPont Innovation Addressing Major Global Market Trends

... in Increasing Food Productivity, Decreasing dependence on Fossil Fuels, Protecting Lives, Growing in ... for increasing food productivity, decreasing dependence on fossil fuels, protecting lives and growing in ... of increasing food productivity, decreasing dependence on fossil fuels and protecting lives. With ...

Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Neurocrine Biosciences Reports First Quarter 2009 Results

... trials; risks associated with the Company's dependence on corporate collaborators for development, ... candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial ...

Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2009 Financial Results

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors

... regulation of the pharmaceutical industry; our dependence on a small number of products and on outside manufacturers for the manufacture of our products; our dependence on third parties to supply raw materials and to ... litigation or claims by the government; our dependence on sales to a limited number of large pharmacy ...

Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences to Sponsor Conference Call

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2008 Financial Results

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008

... elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, ... spending, third-party relationships and revenues; dependence on third parties for supplies, particularly ... having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement ...

Human Genome Sciences Appoints David P. Southwell to its Board of Directors

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2008 Financial Results

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

ViroPharma To Acquire Lev Pharmaceuticals

... a biologics license has been applied, our heavy dependence on the success of Cinryze(TM), our dependence on our suppliers, our dependence on third parties to manufacture Cinryze(TM), ...

Indevus Receives Approvable Letter from FDA for NEBIDO(R)

... elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, ... spending, third-party relationships and revenues; dependence on third parties for supplies, particularly ... having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement ...

Indevus Announces Management Changes

... elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, ... spending, third-party relationships and revenues; dependence on third parties for supplies, particularly ... having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement ...

Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences

... elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, ... spending, third-party relationships and revenues; dependence on third parties for supplies, particularly ... having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement ...

Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty

... elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, ... spending, third-party relationships and revenues; dependence on third parties for supplies, particularly ... having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement ...

Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2008 Financial Results

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...
Other Contents
(Date:11/4/2014)... November 4, 2014   ... growth   Fuel3D , a developer of ... funding round totaling $6.4 million (£4 million). This funding builds ... earlier this year and paves the way for the commercial ... The funding round was led by Chimera Partners and ...
(Date:11/3/2014)... 3, 2014 Research and Markets has ... - Technologies, Markets and Companies" to their offering. ... and methods, which have already started to play an important ... is replacing the old fashioned bone marrow transplants. Role of ... bound to become a part of medical practice. ...
(Date:11/3/2014)... and preterm birth are linked to increased risk for ... the American College of Rheumatology (ACR) journal, Arthritis ... and pre-term babies were not at greater risk of ... According to the ACR, 27 million Americans over the ... of OA range from mild to severe and include ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2
(Date:11/26/2014)... 2014 Increasing demand for diagnostic ... guided surgeries has paved way for consequent increase ... of various types of cancers and cardiac diseases ... demand for these owing to their use in ... injectors market can also be attributed to advancements ...
(Date:11/26/2014)... 2014 Gone are the days when throngs ... Black Friday, which signifies the beginning of the Christmas shopping ... shopping carts in the comfort of their homes or on ... Friday is going to be an occasion with one of ... estimated $2.48 billion in revenue for online retailers according to ...
(Date:11/26/2014)... November 26, 2014 With a redesign ... Dr. Steven Meier has enhanced the user experience ... and prospective patients an online destination for orthopedic and ... to present the new and improved version of the ... it easier than ever for current and prospective patients ...
(Date:11/26/2014)... November 26, 2014 Sonru, the video ... new Chief Operating Officer and Chief Marketing Officer, in ... office. , Jeff Jones has been appointed as ... who takes the role of Chief Marketing Officer. , ... executive whose 25-year career includes senior roles with The ...
(Date:11/26/2014)... 26, 2014 Medical suction and vacuum ... of 5. This score represents steady growth in the ... to 2014 as a result of swelling demand for ... which are largely considered nondiscretionary. IBISWorld market research analyst, ... have some degree of flexibility, given the low level ...
Breaking Medicine News(10 mins):Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:2014 Best Friday Deals Revealed by Top10InAction 2Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:Sonru Expansion continues with appointment of new executive team and opening of new London base 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 4
Other TagsOther Tags